Form 4 for AKBA Akebia Therapeutics, Inc.

Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001619834-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-02-04	2026-02-02	AKBA	Burke Steven Keith	SVP, Chief Medical Off	S - Sale	$1.39	-67.7K	948.4K	-7%	-$94.0K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-02	S	D	25,375	$1.39	969,133	D	—	—	(F3) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. (F1) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
2	Common	Common Stock	2026-02-02	S	D	21,582	$1.39	994,508	D	—	—	(F2) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. (F1) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
3	Common	Common Stock	2026-02-02	S	D	20,701	$1.39	948,432	D	—	—	(F4) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. (F1) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.